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background: Antiplatelet agents are used for secondary prevention in patients with ischemic stroke or transient ischemic attack. Emerging 
studies suggest that early administration of dual antiplatelet therapy (DAPT) may be better than single antiplatelet therapy for the 
prevention of recurrent ischemic stroke, however most of the studies showed increased intracerebral bleeding risk with the use of DAPT. 
We conducted a meta-analysis of randomized controlled trials (RCT) comparing DAPT versus single antiplatelet therapy to evaluate the 
efficacy and safety in reducing the risk of recurrent ischemic stroke.
Methods: Electronic databases were searched to identify RCT that evaluated the effects of DAPT vs. single agent therapy for efficacy 
and safety outcomes in adult with recent ischemic stroke. The primary endpoint was stroke recurrence whereas intracranial bleeding 
complications were recorded as a safety endpoint.
Results: A nine randomized controlled trials were included in the meta-analysis enrolling a total of 45,136 patients. DAPT did not 
significantly reduced risk of stroke recurrence (risk ratio 0.89; 95% CI, 0.788 - 1.023, P 0.10) but when compared with single agent therapy, 
the risk of intracerebral hemorrhage was significantly higher with DAPT (risk ratio 1.31; 95% CI, 1.091 - 1.582, P, 0.004).
conclusion: Compared with single agent antiplatelet therapy, DAPT is not associated with a significant risk reduction in recurrent ischemic 
stroke. DAPT is associated with a significant risk for intracerebral hemorrhage compared with single antiplatelet agent.
